Overview

Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC

Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Oncolytic virus product named Olvi-Vec combined with Platinum plus Etoposide in patients with late phase SCLC
Phase:
PHASE1
Details
Lead Sponsor:
Newsoara Biopharma Co., Ltd.
Collaborators:
Shanghai Chest Hospital
Zhejiang Provincial People's Hospital
Treatments:
Carboplatin
Cisplatin
Etoposide
Platinum